GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
67.63
-0.39 (-0.57%)
At close: 4:00PM EDT

67.60 -0.03 (-0.04%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Previous Close68.02
Open68.15
Bid67.50 x 4000
Ask67.60 x 1200
Day's Range67.25 - 68.57
52 Week Range63.76 - 89.54
Volume4,998,740
Avg. Volume7,276,332
Market Cap87.937B
Beta1.35
PE Ratio (TTM)25.72
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.28 (3.49%)
Ex-Dividend Date2018-06-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
    InvestorPlace3 days ago

    FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs

    The Food and Drug Administration (FDA) announced a shame list of companies that try to block generic drugs in order to ramp up profits.

  • Reuters3 days ago

    EU warns of possible birth defect link to GSK's HIV drug

    Europe's medicines regulator said it was assessing evidence that GlaxoSmithKline's successful HIV drug dolutegravir might be linked to birth defects, adding it should not be prescribed to women seeking to become pregnant. Friday's move by the European Medicines Agency follows preliminary data from a study in Botswana which found four cases of neural tube defects (NTDs), such as spina bifida, in babies born to mothers who became pregnant while taking the drug. Dolutegravir is a so-called integrase inhibitor found in the branded medicines Tivicay and Triumeq, which are sold by GSK's majority-owned ViiV Healthcare unit.

  • The FDA Is Trying To 'Shame' Celgene, Gilead — Here's Why It Won't Work
    Investor's Business Daily4 days ago

    The FDA Is Trying To 'Shame' Celgene, Gilead — Here's Why It Won't Work

    Celgene toppled to a four-year low Thursday after it appeared on a list from the FDA attempting to "shame" drugmakers working to block generic competition.

  • Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics 'gaming' list
    American City Business Journals4 days ago

    Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics 'gaming' list

    Opening another front in President Donald Trump's war on drug prices, the FDA releases a list of companies "gaming" the system to delay lower-priced generics from getting to market.

  • Sangamo Therapeutics Stock History
    Motley Fool4 days ago

    Sangamo Therapeutics Stock History

    After decades of research into gene editing, this biotech company could be on the cusp of developing game-changing new treatments for rare diseases.

  • Taking Stock of Gilead Sciences’ Key Developments
    Market Realist4 days ago

    Taking Stock of Gilead Sciences’ Key Developments

    During the first quarter, Gilead Sciences (GILD) entered into a scientific collaboration with Verily Life Sciences to identify and better understand the immunological basis of three common, serious inflammatory diseases—rheumatoid arthritis, inflammatory bowel disease, and lupus-related diseases—by making use of Verily’s Immunoscape platform.

  • Reuters4 days ago

    FDA names drugmakers likely blocking access to branded drug samples

    The U.S. Food and Drug Administration on Thursday named drugmakers including Celgene Corp, Mylan NV, Gilead Sciences and Novartis AG for potentially blocking access to samples of their products to delay generic competition. Generic drugmakers may not be able to develop alternatives without access to samples of branded products, the FDA said. The regulator said it had heard of some brand companies adopting tactics to make it hard for the generic companies to purchase branded drugs at a fair value and in open market.

  • 3 High-Yield Stocks With Virtual Monopolies
    Motley Fool4 days ago

    3 High-Yield Stocks With Virtual Monopolies

    This trio of high-yield stocks offers dividend investors a lock on key markets with virtual monopolies driving big dividend payments.

  • Gilead Sciences’ Cash Flows, Valuations, and Price Performance
    Market Realist4 days ago

    Gilead Sciences’ Cash Flows, Valuations, and Price Performance

    Gilead Sciences (GILD) stock has corrected 9.6% since the start of 2018 to close at $66.99 on May 15. In comparison, Johnson & Johnson (JNJ), Pfizer (PFE), and Merck & Co. (MRK) have returned -9.5%, -2.1%, and 5.3%, respectively.

  • A Look at Gilead Sciences’ Financial Performance
    Market Realist5 days ago

    A Look at Gilead Sciences’ Financial Performance

    Gilead Sciences’ (GILD) total revenues decreased from $6.5 billion in Q1 2017 to $5.1 billion in Q1 2018, primarily due to lower product sales. The company earns a small part of its revenues from royalty, contract, and other sources. While product sales were $6.3 billion in Q1 2017 and $5 billion in Q1 2018, royalty, contract, and other revenues were $128 million in Q1 2017 and $87 million in Q1 2018.

  • Gilead Sciences’ Product Performance: A Mixed Bag in Q1 2018
    Market Realist5 days ago

    Gilead Sciences’ Product Performance: A Mixed Bag in Q1 2018

    In the first quarter, Gilead Sciences’ (GILD) total product sales decreased to $5 billion from $6.3 billion in the first quarter of 2017. For fiscal 2018 and fiscal 2019, it’s expected to report total revenues of $20.8 billion and $21.1 billion, respectively.

  • Gilead Sciences Stock: How Much Upside Do Analysts Expect?
    Market Realist5 days ago

    Gilead Sciences Stock: How Much Upside Do Analysts Expect?

    Gilead Sciences (GILD) is a research-based biopharmaceutical company focused on discovering, developing, and bringing to market innovative medicines for life-threatening diseases. Gilead released its first-quarter earnings on May 4. Of the 26 analysts covering Gilead Sciences stock in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.2 with a target price of $85.81, which implies an upside potential of 27.2% over its closing price of $66.99 on May 15.

  • Breakout Watch: Biotech Stock With 172% Growth Enters Buy Zone
    Investor's Business Daily5 days ago

    Breakout Watch: Biotech Stock With 172% Growth Enters Buy Zone

    Leading biotech stock and IBD 50 member Ligand Pharmaceuticals is in a buy zone after reporting 172% earnings growth.

  • MarketWatch7 days ago

    Why Trump’s drug-price pitch makes no sense

    Donald Trump’s speech on drug prices on Friday was no surprise — it was his usual mishmash of pseudo-populist nonsense, obscuring the standard-issue corporatist Republican agenda he reverts to when he knows nothing, which is most of the time. The speech abandoned one of the few more-or-less populist campaign promises the president made in 2016 — to have Medicare begin negotiating over drug prices, reversing a law his party passed specifically to maximize drug-company profits.

  • CNBC10 days ago

    Cramer says it's 'very hard to put a price on' lifesaving drugs

    President Trump on Friday is set to release a plan aimed at cutting prescription drug costs. But Jim Cramer argues some drugs may be worth it.

  • Cramer says it's 'very hard to put a price on' lifesaving drugs
    CNBC10 days ago

    Cramer says it's 'very hard to put a price on' lifesaving drugs

    President Trump on Friday is set to release a plan aimed at cutting prescription drug costs. But Jim Cramer argues some drugs may be worth it.

  • Investopedia11 days ago

    Gilead May Rebound By 12% Short Term

    Gilead Sciences Inc. ( GILD) shares appear poised to rebound by about 12%, taking the stock back to around $72. Revenue missed estimates by nearly 6%, coming in at $5.088 billion, while earnings missed estimates by 11.25% at $1.48, resulting in shares plunging by 9.5%. The chart below shows that Gilead shares have reached a critical support level around $64 and has so far been able to remain above it.

  • Analysts’ Recommendations for Regeneron Pharmaceuticals in May
    Market Realist12 days ago

    Analysts’ Recommendations for Regeneron Pharmaceuticals in May

    In April 2018, the FDA accepted for priority review Regeneron Pharmaceuticals (REGN) and Sanofi’s (SNY) Biologics License Application (or BLA) for cemiplimab for the treatment of individuals with metastatic CSCC (cutaneous squamous cell carcinoma) or individuals with locally advanced CSCC who cannot be treated with surgery. In September 2017, the FDA granted cemiplimab Breakthrough Therapy designation status for the treatment of metastatic CSCC. The FDA provided a Prescription Drug User Fee Act action date of October 28, 2018.

  • Why Bristol-Myers Squibb Stock Crashed in April
    Motley Fool12 days ago

    Why Bristol-Myers Squibb Stock Crashed in April

    The company's stock hasn't been this cheap in years. Time to buy?

  • 3 Stocks That Turned $10,000 Into $1 Million
    Motley Fool13 days ago

    3 Stocks That Turned $10,000 Into $1 Million

    These three biotech stocks delivered monster returns over the past couple of decades. Here's how.

  • What Investors Should Know About Gilead Sciences Inc’s (NASDAQ:GILD) Financial Strength
    Simply Wall St.13 days ago

    What Investors Should Know About Gilead Sciences Inc’s (NASDAQ:GILD) Financial Strength

    Gilead Sciences Inc (NASDAQ:GILD), a large-cap worth US$85.05B, comes to mind for investors seeking a strong and reliable stock investment. Risk-averse investors who are attracted to diversified streams of revenueRead More...

  • Why Sangamo Therapeutics Stock Dropped Today
    Motley Fool13 days ago

    Why Sangamo Therapeutics Stock Dropped Today

    Valuing early-stage biotechs is hard.

  • Reuters14 days ago

    UK biotech firm Autolus joins CAR-T rush with Nasdaq IPO filing

    Autolus Therapeutics, a small British company developing cell therapy treatments, is to join the swelling ranks of listed biotech companies using the new anti-cancer technology with a planned IPO on Nasdaq. The group said on Tuesday it had filed a registration statement with the U.S. Securities and Exchange Commission for a proposed initial public offering (IPO) under the ticker symbol AUTL. The number of its American depositary shares to be sold in the IPO and the pricing terms have not yet been determined.

  • Final Trade: IBB, GILD & more
    CNBC Videos10 days ago

    Final Trade: IBB, GILD & more

    The "Fast Money" traders share their final trades of the day, including Ethereum, Match, the IBB and Gilead.

  • You should know the cost of a drug or procedure before it...
    CNBC Videos10 days ago

    You should know the cost of a drug or procedure before it...

    Sen. Bill Cassidy (R-La.) discusses Trump's plan to lower drug prices.